|
1
|
De Witt Hamer PC, Robles SG, Zwinderman A,
Duffau H and Berger M: Impact of intraoperative stimulation brain
mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol.
30:2559–2565. 2012.PubMed/NCBI
|
|
2
|
Smith JS, Chang EF, Lamborn KR, et al:
Role of extent of resection in the long-term outcome of low-grade
hemispheric gliomas. J Clin Oncol. 26:1338–1345. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sanai N and Berger MS: Glioma extent of
resection and its impact on patient outcome. Neurosurgery.
6:753–764. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Benjamin R, Capparella J and Brown A:
Classification of glioblastoma multiforme in adults by molecular
genetics. Cancer J. 9:82–90. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Behin A, Hoang-Xuan K, Carpentier AF and
Delattre JY: Primary brain tumours in adults. Lancet. 361:323–331.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Höckel M, Schlenger K, Mitze M, Schäffer U
and Vaupel P: Hypoxia and radiation response in human tumors. Semin
Radiat Oncol. 6:3–9. 1996.
|
|
8
|
Unruh A, Ressel A, Mohamed HG, et al: The
hypoxia-inducible factor-1α is a negative factor for tumor therapy.
Oncogene. 22:3213–3220. 2003.
|
|
9
|
Ahmad SS, Glatzle J, Bajaeifer K, et al:
Phosphoglycerate kinase 1 as a promoter of metastasis in colon
cancer. Int J Oncol. 43:586–590. 2013.PubMed/NCBI
|
|
10
|
Chen G, Gharib TG, Wang H, et al: Protein
profiles associated with survival in lung adenocarcinoma. Proc Natl
Acad Sci USA. 100:13537–13542. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zieker D, Königsrainer I, Tritschler I, et
al: Phosphoglycerate kinase 1 a promoting enzyme for peritoneal
dissemination in gastric cancer. Int J Cancer. 126:1513–1520.
2010.PubMed/NCBI
|
|
12
|
Wang J, Ying G, Wang J, et al:
Characterization of phosphoglycerate kinase-1 expression of stromal
cells derived from tumor microenvironment in prostate cancer
progression. Cancer Res. 70:471–480. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang J, Wang J, Dai J, et al: A glycolytic
mechanism regulating an angiogenic switch in prostate cancer.
Cancer Res. 67:149–159. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cecconi D, Palmieri M and Donadelli M:
Proteomics in pancreatic cancer research. Proteomics. 11:816–828.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lincet H, Guével B, Pineau C, et al:
Comparative 2D-DIGE proteomic analysis of ovarian carcinoma cells:
toward a reorientation of biosynthesis pathways associated with
acquired platinum resistance. J Proteomics. 75:1157–1169. 2012.
View Article : Google Scholar
|
|
16
|
Duan Z, Lamendola DE, Yusuf RZ, Penson RT,
Preffer FI and Seiden MV: Overexpression of human phosphoglycerate
kinase 1 (PGK1) induces a multidrug resistance phenotype.
Anticancer Res. 22:1933–1941. 2002.PubMed/NCBI
|
|
17
|
Yan H, Yang K, Xiao H, Zou YJ, Zhang WB
and Liu HY: Over-expression of cofilin-1 and phosphoglycerate
kinase 1 in astrocytomas involved in pathogenesis of
radioresistance. CNS Neurosci Ther. 18:729–736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ding H, Cheng YJ, Yan H, et al:
Phosphoglycerate kinase 1 promotes radioresistance in U251 human
glioma cells. Oncol Rep. 31:894–900. 2014.PubMed/NCBI
|
|
19
|
Wu W and Zhao S: Metabolic changes in
cancer: beyond the Warburg effect. Acta Biochim Biophys Sin.
45:18–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gatenby RA and Gillies RJ: Why do cancers
have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seemann MD: PET/CT: fundamental
principles. Eur J Med Res. 9:241–246. 2004.PubMed/NCBI
|
|
22
|
Zhang DH, Tai LK, Wong LL, Chiu LL, Sethi
SK and Koay ES: Proteomic study reveals that proteins involved in
metabolic and detoxification pathways are highly expressed in
HER-2/neu-positive breast cancer. Mol Cell Proteomics.
4:1686–1696. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luo FM, Liu XJ, Yan NH, et al:
Hypoxia-inducible transcription factor-1α promotes hypoxia-induced
A549 apoptosis via a mechanism that involves the glycolysis
pathway. BMC Cancer. 6:262006.
|
|
24
|
Qing G, Skuli N, Mayes PA, et al:
Combinatorial regulation of neuroblastoma tumor progression by
N-Myc and hypoxia inducible factor HIF-1α. Cancer Res.
70:10351–10361. 2010.PubMed/NCBI
|
|
25
|
Aebersold DM, Burri P, Beer KT, et al:
Expression of hypoxia-inducible factor-1α: a novel predictive and
prognostic parameter in the radiotherapy of oropharyngeal cancer.
Cancer Res. 61:2911–2916. 2001.
|
|
26
|
Ryan HE, Lo J and Johnson RS: HIF-1 alpha
is required for solid tumor formation and embryonic
vascularization. EMBO J. 17:3005–3015. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu H, Forbes RA and Verma A:
Hypoxia-inducible factor 1 activation by aerobic glycolysis
implicates the Warburg effect in carcinogenesis. J Biol Chem.
277:23111–23115. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rodríguez-Enríquez S and Moreno-Sánchez R:
Intermediary metabolism of fast-growth tumor cells. Arch Med Res.
29:1–12. 1998.
|
|
29
|
Hsu PP and Sabatini DM: Cancer cell
metabolism: Warburg and beyond. Cell. 134:703–707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ward JF: Radiation mutagenesis: the
initial DNA lesions responsible. Radiat Res. 142:362–368. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
VandeBerg JL: The phosphoglycerate kinase
isozyme system in mammals: biochemical, genetic, developmental, and
evolutionary aspects. Isozymes Curr Top Biol Med Res. 12:133–187.
1985.PubMed/NCBI
|
|
32
|
Popanda O, Fox G and Thielmann HW:
Modulation of DNA polymerases α, δ and ɛ by
lactate dehydrogenase and 3-phosphoglycerate kinase. Biochim
Biophys Acta. 1397:102–117. 1998.PubMed/NCBI
|
|
33
|
Vishwanatha JK, Jindal HK and Davis RG:
The role of primer recognition proteins in DNA replication:
association with nuclear matrix in HeLa cells. J Cell Sci.
101:25–34. 1992.PubMed/NCBI
|
|
34
|
McCord AM, Jamal M, Williams ES,
Camphausen K and Tofilon PJ: CD133+ glioblastoma
stem-like cells are radiosensitive with a defective DNA damage
response compared with established cell lines. Clin Cancer Res.
15:5145–5153. 2009.
|
|
35
|
Narayana A, Gruber D, Kunnakkat S, et al:
A clinical trial of bevacizumab, temozolomide, and radiation for
newly diagnosed glioblastoma. J Neurosurg. 116:341–345. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bao S, Wu Q, McLendon RE, et al: Glioma
stem cells promote radioresistance by preferential activation of
the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zieker D, Bühler S, Ustündag Z, et al:
Induction of tumor stem cell differentiation - novel strategy to
overcome therapy resistance in gastric cancer. Langenbecks Arch
Surg. 398:603–608. 2013. View Article : Google Scholar : PubMed/NCBI
|
